RTSL OTC
Rapid Therapeutic Science Laboratories, Inc.
1W: +0.0%
1M: +0.0%
3M: +300.0%
YTD: -80.0%
1Y: -86.7%
3Y: -99.9%
5Y: -99.9%
$0.00
+0.00 (+0.00%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
-$24K
+0.0% ▲
Operating Income
-$83K
+0.0% ▲
Net Income
-$183K
+0.0% ▲
EPS (Diluted)
$-0.01
+0.0% ▲
EBITDA
-$59K
+0.0% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2017 | FY2019 | FY2021 | FY2022 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $0 | $9K | $534 | $0 | $0 |
| YoY Growth | +0.0% | +0.0% | +0.0% | -100.0% | +0.0% |
| Cost of Revenue | $0 | $7K | $200 | $0 | $24K |
| Gross Profit | $0 | $2K | $334 | $0 | -$24K |
| Gross Margin | — | 21.7% | 62.5% | — | — |
| R&D Expenses | $0 | $0 | $0 | $0 | $0 |
| SG&A Expenses | $136K | $170K | $2M | $1M | $59K |
| Operating Expenses | $152K | $170K | $2M | $1M | $59K |
| Operating Income | -$3M | -$170K | -$2M | -$1M | -$83K |
| Operating Margin | — | -1856.8% | -406422.3% | — | — |
| Interest Expense | $29K | $181K | $1M | $2M | $100K |
| Income Before Tax | -$3M | -$349K | -$3M | -$2M | -$183K |
| Tax Expense | $29K | -$1K | $1M | -$101K | $0 |
| Net Income | -$3M | -$349K | -$4M | -$2M | -$183K |
| Net Margin | — | -3817.1% | -786015.7% | — | — |
| EPS (Diluted) | $-25.88 | $-7.24 | $-0.55 | $-0.22 | $-0.01 |
| EBITDA | -$136K | -$168K | -$2M | -$1M | -$59K |
| Shares Outstanding | 98643 | 48160 | 8M | 8M | 19M |